Aptevo Therapeutics Inc. announced that APVO436, in combination with venetoclax and azacitidine, achieved a 100% clinical benefit rate (CBR) in venetoclax treatment naïve AML patients. The data, which was presented in a poster session at the 64thAmerican Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, also showed that APVO436, when given in combination with this standard-of-care regimen, was observed to be generally safe and well tolerated.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 USD | +0.48% | -10.11% | -89.95% |
05-08 | Aptevo Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-11 | US Equity Markets Close Mixed After March Producer Price Inflation Data | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-89.95% | 1.29M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- APVO Stock
- News Aptevo Therapeutics Inc.
- Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate in Venetoclax Treatment Naïve AML Patients